Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aveo Pharmaceuticals (NQ: AVEO )

5.340 USD -0.380 (-6.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 341,239
Open 5.690
Bid (Size) 5.110 (3)
Ask (Size) 5.360 (1)
Prev. Close 5.720
Today's Range 5.290 - 5.710
52wk Range 4.950 - 18.24
Shares Outstanding 34,373,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be... 
From Business Wire News Releases
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in two upcoming virtual... 
From Business Wire News Releases

Performance

YTD
-10.55%
-10.55%
1 Month
-26.95%
-26.95%
3 Month
-17.21%
-17.21%
6 Month
-25.73%
-25.73%
1 Year
-0.56%
-0.56%

More News

Read More
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
From Business Wire News Releases
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
From Business Wire News Releases
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
From Business Wire News Releases
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
From Business Wire News Releases
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
From Business Wire News Releases
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
From Business Wire News Releases
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
From Business Wire News Releases
AVEO Makes Bullish Cross Above Critical Moving Average
Tags Stocks
From Market News Video
AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.